
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc. demonstrated significant financial growth in 2024, with biopharma testing and services revenue surging by 59% to $51 million, compared to $32 million in 2023, indicating strong demand for its genomic solutions. Additionally, the company's gross margin improved by 50 basis points year-over-year to reach 27.1% in 4Q24, surpassing the consensus forecast, driven by a favorable customer mix and increased biopharma volume. The company is strategically increasing its cash burn to enhance commercial capabilities in anticipation of potential reimbursement for its NeXT Personal product in the second half of 2025, further signifying its commitment to growth and market expansion.
Bears say
Personalis Inc. reported a 15% decline in 4Q24 revenue, amounting to $16.8 million, which was below market consensus, indicating continuing financial struggles. The company's reliance on the ImmunoID NeXT platform raises concerns about future revenue sustainability, particularly with anticipated slower growth in biopharma revenues and diminished contributions from key clients like Natera. Additionally, significant risks such as reduced customer adoption of new offerings and intensified competition further exacerbate the negative outlook for Personalis's stock, suggesting challenges in achieving projected growth targets.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares